FIGURE 2.
Cytochrome c release assay with Bcl-xL BH3 peptides. Permeabilized MEFs were treated with the indicated concentrations of synthetic peptides corresponding to the wild-type Bcl-xL BH3 domain (wt), the wild-type Bcl-xL BH3 domain fused to a mitochondrial targeting sequence (wt-MTS), or the Bcl-xL h1 + 1/h3 mutant BH3 domain fused to a mitochondrial targeting sequence (mt3-MTS) (left) or the wild-type Bim BH3 domain (wt) or the wild-type Bim BH3 domain fused to a mitochondrial targeting sequence (wt-MTS) (right). The presence of cytochrome c released into the soluble fraction following peptide treatment was determined by Western blotting (WB) with an anti-cytochrome c antibody.